Navigation Links
Dey Issues Advisory
Date:9/13/2009

NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today issued an advisory regarding the theft of two different types of its respiratory medications, Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The lots were on a tractor-trailer that was stolen in the state of Florida.

The NDC numbers for the Ipratropium product are 49502-685-31 (lot number F09089) and 49502-685-62 (lot numbers C09119 and C09120). All packages contain 2.5 ml vials and display the brand name "DEY."

The NDC numbers for the Albuterol product are 49502-697-29 (lot number 9G04) and 49502-697-61 (lot numbers 9FD8, 9FD9 and 9FE1). All packages contain 3.0 ml vials and display the brand name "DEY."

In the weeks prior to the truck theft, some portion of each lot had been sold by Dey to its customers and successfully entered the legitimate pharmaceutical supply chain. Because the stolen product may have been stored or handled improperly, Dey is requesting that any and all product with the affected lot numbers be isolated and not be dispensed, sold or used. Dey has alerted its distributors and customers.

Anyone who has information about this incident, has received suspicious or unsolicited offers for the products in question or received product from these lots is encouraged to contact the U.S. Food and Drug Administration (FDA) Office of Criminal Investigations at 1.800.551.3989. Patient or customer inquiries for the company should be directed to Dey Customer Service at 1.800.527.4278.

Dey discourages patients from purchasing any medication sold outside of legitimate channels.

Dey L.P., a subsidiary of Mylan Inc. (NASDAQ: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova issues clarifying press release
2. Lifeline Issues Safety Notice to Subscribers
3. Healthcare Legal Issues Take the Stage at PAINWeek 2009
4. Private Care Association to Tackle Major Issues Impacting Home Care Industry
5. Crohn's & Colitis Foundation Issues Annual Report
6. Memorial Blood Centers Issues a Critical Alert For Blood Donations
7. PRA International Chairs Session on Post Marketing Safety Issues
8. U.S. Issues Swine Flu Guidelines for Day-Care Programs
9. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
10. Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials
11. San Francisco Mayor Gavin Newsom Talks About Immigration and Drugs on Azteca Americas Issues: Caras y Voces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy ... adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), ... “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Joseph Health held the much anticipated Regional Primary Care Spring Symposium on April ... in the local medical community, offering physicians and healthcare providers an opportunity to ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology: